CD274 and nonpapillary renal cell carcinoma: Recent clinical commercialization of PD-1 pathway inhibitors (nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab) has raised interest in PD-1 and PD-L1 expression as potential markers of response to immune checkpoint therapy in several malignancies, including CCRCC [19].